Diagnostic Imaging Therapeutics
1. Definity patent expiration
Treatment: Method of using the drug substance/drug product for ultrasound imaging
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685441 | LANTHEUS MEDCL | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jan, 2019
(6 years ago) | |
| US5585112 | LANTHEUS MEDCL | Method of preparing gas and gaseous precursor-filled microspheres |
Dec, 2013
(12 years ago) | |
| US6033645 | LANTHEUS MEDCL | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
Jun, 2016
(9 years ago) | |
| US5527521 | LANTHEUS MEDCL | Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications |
Feb, 2015
(10 years ago) | |
| US9545457 | LANTHEUS MEDCL | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jan, 2019
(6 years ago) | |
| US8658205 | LANTHEUS MEDCL | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jun, 2019
(6 years ago) | |
| US11925695 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(11 years from now) | |
| US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(11 years from now) | |
| US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(11 years from now) | |
| US10583207 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(9 years from now) | |
| US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(11 years from now) | |
| US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(11 years from now) | |
| US11857646 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(11 years from now) | |
| US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(11 years from now) | |
| US12161730 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(11 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Dosage: INJECTABLE
More Information on Dosage
DEFINITY family patents
2. Elucirem patent expiration
Treatment: NA
ELUCIREM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(2 years from now) | |
| US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590246 | GUERBET | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process |
Jan, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Dosage: SOLUTION
More Information on Dosage
ELUCIREM family patents
3. Gadavist patent
expiration
Treatment: Contrast agent for magnetic resonance imaging
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2016 |
| New Indication(I-688) | Jun 11, 2017 |
| New Indication(I-731) | Apr 27, 2019 |
| New Indication(I-801) | Jul 12, 2022 |
Drugs and Companies using GADOBUTROL ingredient
NCE-1 date: 15 March, 2015
Market Authorisation Date: 18 December, 2013
Dosage: SOLUTION
More Information on Dosage
GADAVIST family patents
4. Imagent patent expiration
Treatment: Method of use of imagent
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5798091 | VESSELON SPV LLC | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
Aug, 2015
(10 years ago) | |
| US6280704 | VESSELON SPV LLC | Ultrasonic imaging system utilizing a long-persistence contrast agent |
Jul, 2013
(12 years ago) | |
| US5605673 | VESSELON SPV LLC | Stabilized microbubble compositions for ultrasound |
Feb, 2014
(11 years ago) | |
| US5626833 | VESSELON SPV LLC | Ultrasound imaging method using microbubbles |
May, 2014
(11 years ago) | |
| US5695741 | VESSELON SPV LLC | Stable microbubble precursors |
Dec, 2014
(11 years ago) | |
| US6280705 | VESSELON SPV LLC | Kits & systems for ultrasonic imaging |
Jul, 2013
(12 years ago) | |
| US5639443 | VESSELON SPV LLC | Stabilized microbubble compositions |
Jun, 2014
(11 years ago) | |
| US5720938 | VESSELON SPV LLC | Systems for the formation of microbubbles |
Feb, 2015
(10 years ago) | |
| US6287539 | VESSELON SPV LLC | Methods of imaging using osmotically stabilized microbubble preparations |
Jul, 2013
(12 years ago) | |
Drugs and Companies using DIMYRISTOYL LECITHIN; PERFLEXANE ingredient
Market Authorisation Date: 31 May, 2002
Dosage: INJECTABLE
More Information on Dosage
IMAGENT family patents
5. Lumisight patent expiration
Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9763577 | LUMICELL | Imaging agent for detection of diseased cells |
Sep, 2034
(8 years from now) | |
| US11592396 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Sep, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9532835 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(5 years from now) | |
| US9155471 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Oct, 2031
(5 years from now) | |
| US9032965 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(5 years from now) | |
| US10285759 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Dosage: POWDER
More Information on Dosage
LUMISIGHT family patents